At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 26, 2026 at 07:00 ET
Lifecore Biomedical announced two new CDMO manufacturing agreements with an existing U.S. biopharmaceutical customer: one for a commercial site transfer of a currently marketed product, and another to expand manufacturing of an ophthalmic product into a new delivery system previously made in Europe. These agreements are expected to contribute to commercial revenue starting in 2028 and mark the company's fourth site transfer win in five months, reinforcing its strategic focus on late-stage, high-value programs.
- Lifecore signed two manufacturing agreements with an existing U.S. biopharmaceutical customer.
- One agreement involves a commercial site transfer of a currently marketed product, requiring technical transfer and PPQ batches at commercial scale.
- The second agreement expands manufacturing of an ophthalmic product to a new delivery system, shifting production from Europe to Lifecore.
- These are the fourth commercial site transfer agreements signed in five months.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access